" class="no-js "lang="en-US"> CNS Pharmaceuticals Appoints New Chair of the Board of Directors
Sunday, April 21, 2024

CNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of Directors

CNS Pharmaceuticals, a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced it has appointed Faith Charles as Chair of its Board of Directors.

“The depth and breadth of knowledge, experience and network that Faith brings to our Board will be invaluable to CNS Pharma. We are thrilled to welcome her and look forward to leveraging her expertise as we continue to execute on our clinical development, drive future growth and create shareholder value in the near and long term,” commented John Climaco, CEO of CNS Pharmaceuticals.

Ms. Charles has been a corporate transactions and securities partner at the law firm of Thompson Hine, LLP, since 2010. She currently leads Thompson Hine’s Life Sciences practice and co-heads the securities practice, advising public and emerging biotech and pharmaceutical companies in the U.S. and internationally. Ms. Charles negotiates complex private and public financing transactions, mergers and acquisitions, licensing transactions and strategic collaborations.

Ms. Charles currently serves on the Board of Directors of Avenue Therapeutics, a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases and on the Board of Directors, Audit Committee and Nominating and Corporate Governance Committee of Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases whose common stock is listed on the Nasdaq. From 2018 until October 2021, Ms. Charles served on the Board of Directors and as a member of the Audit Committee and Chair of the Compensation Committee of Entera Bio Ltd., a publicly-traded biotechnology company. Ms. Charles founded the Women in Bio Metro New York chapter and chaired the chapter for five years and served on the Women and Bio National Board for over 3 years. Ms. Charles is also a member of the Board of Red Door Community formerly Gilda’s Club New York City. She has been recognized as a Life Sciences Star by Euromoney’s LMG Life Sciences, has been named a BTI Client Service All-Star, and was named by Crain’s New York Business to the list of 2020 Notable Women in the Law.

“CNS Pharmaceuticals has continually demonstrated their dedication to GBM patients and driving their clinical development of Berubicin forward. While operated by a lean and mighty management team, they have made significant advancements and I believe are in a position to positively impact the GBM treatment space, where there remains significant unmet need. I am pleased to join the Company’s Board of Directors and offer insights from experiences amassed over the course of my career to help guide their clinical development program and corporate growth,” added Ms. Charles.

Ms. Charles holds a JD degree from The George Washington University Law School and a B.A. in Psychology from Barnard College, Columbia University. Ms. Charles is a graduate of Women in Bio’s Boardroom Ready Program, an Executive Education Program taught by The George Washington University School of Business.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more